AZ's lead ATR inhibitor, in combination with olaparib (PARP inhibitor) or durvalumab. LATIFY P3 in NSCLC missed primary endpoint May 2024; salvage trials in melanoma and biliary cancer continuing.
AZ's lead ATR inhibitor, in combination with olaparib (PARP inhibitor) or durvalumab. LATIFY P3 in NSCLC missed primary endpoint May 2024; salvage trials in melanoma and biliary cancer continuing.
LATIFY (n=594, NSCLC) MISSED primary OS endpoint May 2024; ceralasertib + durvalumab did not improve OS vs docetaxel after PD-(L)1 + platinum. Dataset shows 2 P3 trials still active — salvage trials in melanoma and biliary cancer continuing per AZ.
Regulatory: Lead indication failed. Watching FY-2025 10-K for IPR&D impairment language.
LATIFY P3 (NSCLC + durvalumab): missed primary endpoint May 2024
Who else is racing? — 3 other assets at ATR
Asset
Sponsor
Status
Camonsertib (RP-3500)
Repare Therapeutics
P1/P2
Elimusertib (BAY1895344)
Bayer
P1
Tuvusertib (M1774)
Merck KGaA
P1/P2
What conditions is it being studied for?
89 distinct conditions after collapsing staging variants
· 115 raw entries from ClinicalTrials.gov
or Metastatic Non-Small Cell Lung CancerLung Non-Small Cell CarcinomaLung CancerNon-Small Cell Lung CancerCarcinoma, Squamous CellAdenocarcinomaPediatric CancerHigh Grade Serous CarcinomaSCLCFallopian Tube CarcinomaOvarian CarcinomaPrimary Peritoneal CarcinomaAnatomic Stage IV Breast CancerTriple-Negative Breast CarcinomaClear Cell Renal Cell CarcinomaPancreatic CancerMalignant Solid NeoplasmRenal Cell CarcinomaUrothelial CarcinomaRenal Cell CancerEndometrial CancerCastration-resistant Prostate CancerBreast NeoplasmTriple Negative Breast CancerHRDProstate CancerGynaecological CancersCholangiocarcinomaBile Duct CancerChemotherapy EffectBreast CarcinomaAnatomic Stage III Breast CancerAnatomic Stage IIIA Breast CancerAnatomic Stage IIIB Breast CancerAnatomic Stage IIIC Breast CancerGermline BRCA1 Gene MutationGermline BRCA2 Gene MutationHER2/Neu NegativePrognostic Stage III Breast CancerPrognostic Stage IIIA Breast CancerPrognostic Stage IIIB Breast CancerPrognostic Stage IIIC Breast CancerPrognostic Stage IV Breast CancerOvarian CancerOsteosarcomaOsteosarcoma RecurrentSolid TumoursExtensive Stage Small Cell Lung CancerMelanomaTriple Negative Breast Cancer Metastaticor Metastatic NSCLCNon Small Cell Lung Cancer NSCLCExtensive Stage Lung Small Cell CarcinomaLung Small Cell Carcinoma, A SubtypeLung Small Cell Carcinoma, I SubtypeLung Small Cell Carcinoma, N SubtypeLung Small Cell Carcinoma, P SubtypeHead and Neck Squamous Cell CarcinomaChronic Lymphocytic LeukemiaNHLDLBCLNon-hodgkin's LymphomaDiffuse Large B Cell LymphomaLeukemiaMyelodysplastic SyndromeNon Small Cell Lung CancerColon CarcinomaColorectal CarcinomaEndometrial CarcinomaGastric CarcinomaGastroesophageal Junction AdenocarcinomaSalivary Gland CarcinomaGastric CancerHER2-Positive Breast CarcinomaMalignant Hepatobiliary NeoplasmColon CancerColorectal CancerMajor Salivary Gland CancerUterine Corpus Carcinoma or CarcinosarcomaUnresectable Breast CarcinomaUnresectable Colon CarcinomaUnresectable Colorectal CarcinomaUnresectable Endometrial CarcinomaUnresectable Gastric CarcinomaUnresectable Gastroesophageal Junction AdenocarcinomaUnresectable Malignant Solid NeoplasmUnresectable Salivary Gland CarcinomaSolid MalignanciesNeoplasm
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.
